Abstract:Drug-induced liver injury (DILI) encompasses a spectrum of clinical disease ranging from mild biochemical abnormalities to acute liver failure. The majority of adverse liver reactions are idiosyncratic, occurring in most instances 5-90 days after the causative medication was last taken. The diagnosis of DILI is clinical, based on history, probability of the suspect medication as a cause of liver injury and exclusion of other hepatic disease. DILI can be hepatocellular (predominant rise in alanine transaminase), cholestatic (predominant rise in alkaline phosphatase) or mixed liver injury. An elevated bilirubin level more than twice the upper limit of normal in patients with hepatocellular liver injury implies severe DILI, with a mortality of approximately 10% and with an incidence rate of 0.7-1.3 per 100,000. Although acute liver failure is rare, 13-17% of all acute liver failure cases are attributed to idiosyncratic drug reactions. Response to drug withdrawal may be delayed up to 1 year with cholestatic liver injury with occasional subsequent progressive cholestasis known as the vanishing bile duct syndrome. Overall, chronic disease may occur in up to 6% even if the offending drug is withdrawn. Antibiotics and NSAIDs are the most common cause of DILI. Statins rarely cause significant liver injury whereas antiretroviral therapy is associated with hepatotoxicity in 10% of treated patients. Multiple mechanisms of DILI have been implicated, including TNF-alpha-activated apoptosis, inhibition of mitochondrial function and neoantigen formation. Risk factors for DILI include age, sex and genetic polymorphisms of drug-metabolising enzymes such as cytochrome P450. In patients with human immunodeficiency virus, the presence of chronic viral hepatitis increases the risk of antiretroviral therapy hepatotoxicity. Over the next decade, the combination of accurate case ascertainment of DILI via clinical networks and the application of genomics and proteomics will hopefully lead to accurate prediction of risk of DILI, so that pharmacotherapy can be optimised with avoidance of adverse hepatic events.

S4443 A Case of Drug-Induced Liver Injury Caused by Mushroom Gummy Ingestion

An Analysis of the Efficacy and Safety of Compound Glycyrrhizin Injections in the Treatment of Drug-Induced Liver Injury Using a Nationwide Database.

S4269 A K(NAC)K for DILI

S4684 Rare Case of Drug-Induced Liver Injury Secondary to Benadryl Use

S4431 A Severe Case of Drug-Induced Liver Injury After Ingestion of Amoxicillin-Clavulanic Acid

ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury

S4241 Attack of the Maca: Drug-Induced Liver Injury Secondary to Lepidium meyenii

[The Clinical Features and Prognosis of Drug-Induced Liver Disease].

A unusual presentation of liver failure caused by Ibuprofen-sustained release capsules: A case report

Idiosyncratic drug-induced liver injury: an overview

Severe Drug-Induced Liver Injury From Over-the-Counter Medication

Liver Injury with Nintedanib: A Pharmacovigilance-Pharmacokinetic Appraisal

S4576 Unique Case of Vanishing Bile Duct Syndrome Exacerbated by Noncompliance

S4244 Acute Hepatocellular Injury Induced by Pre-Workout Supplements

Investigation of the Role of Chemical Analysis in Causality Assessment of Herbal and Dietary Supplement-Induced Liver Injury

A new prognostic model for drug-induced liver injury especially suitable for Chinese population

[Drug-induced autoimmune-like liver injury]

Understanding of ACG Clinical Guideline:Diagnosis and Management of Idiosyncratic Drug-induced Liver Injury

S4397 Drug-Induced Liver Injury Secondary to Recent Ozempic use

Clinical Characteristics of Patients with Drug-induced Liver Injury.

Drug-induced Liver Injury: an Analysis of 231 Cases